Spots Global Cancer Trial Database for First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Official Title: An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Study ID: NCT03188965
Interventions
Study Description
Brief Summary: The ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given to cancer patients. Further, the response of the cancer to the treatment will be determined.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope National Medical Center, Duarte, California, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Emory University, Atlanta, Georgia, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Weill Cornell Medical College, New York, New York, United States
Gabrail Cancer Center, Canton, Ohio, United States
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
US Oncology / Eugene, Eugene, Oregon, United States
Jefferson Medical College, Philadelphia, Pennsylvania, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Texas Oncology- San Antonio Northeast, San Antonio, Texas, United States
University of Utah - Oncology, Salt Lake City, Utah, United States
Fairfax-Northern Virginia Hematology/Oncology, PC, Fairfax, Virginia, United States
Cross Cancer Institute, Edmonton, Alberta, Canada
OHRI - The Ottawa Hospital, Ottawa, Ontario, Canada
Integrated Cancer Center of the CHU de Québec, Quebec, , Canada
Beijing Cancer Hospital, Beijing, , China
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Shizuoka Cancer Center, Sunto, Shizuoka, Japan
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
National University Hospital, Singapore, , Singapore
National Cancer Center Singapore, Singapore, , Singapore
Hôpital Cantonal Universitaire de Genève, Geneva, Genève, Switzerland
Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland
Oncology Institute of Southern Switzerland, Bellinzona, , Switzerland
Velindre Hospital, Cardiff, South Glamorgan, United Kingdom
Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom
Freeman Hospital, Newcastle Upon Tyne, Tyne And Wear, United Kingdom
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
